Novel Agents and Incremental Advances in the Treatment of Head and Neck Cancer

Fadlo R. Khuri, Sanjay R. Jain

Research output: Contribution to journalArticle

Abstract

Cancer of the head and neck is an important medical problem, with approximately 46,500 cases predicted in the United States alone in 2003. Worldwide, more than 600,000 cases are anticipated. While several different histologic subtypes of head and neck cancer are seen in different parts of the world, more than 90% of tumors diagnosed in the United States are squamous cell carcinomas. Major strides in the management of this disease have been made in the last decade. These include, but are not limited to, the evolution of organ preservation, the increasingly well recognized role of concurrent chemoradiation therapy as either definitive therapy for unresectable disease or adjuvant therapy for high-risk surgical disease, and significant improvements in cytotoxic chemotherapy. The role of chemotherapy in this disease has been a subject of debate. Chemotherapy is now routinely included in the multimodality treatment of unresectable disease of the oral pharynx, larynx, and oral cavity. There is now increasing evidence supporting the role of induction chemotherapy in head and neck cancer. As intensified chemotherapy and radiation therapy have improved local control, the increasing incidence of distant metastases has necessitated the need for enhanced systemic control. These approaches are the topics of extensive investigations.

Original languageEnglish (US)
Pages (from-to)3-10
Number of pages8
JournalSeminars in Oncology
Volume31
Issue number2 SUPPL. 4
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Drug Therapy
Pharyngeal Diseases
Organ Preservation
Induction Chemotherapy
Therapeutics
Larynx
Disease Management
Mouth
Squamous Cell Carcinoma
Radiotherapy
Neoplasm Metastasis
Incidence
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Novel Agents and Incremental Advances in the Treatment of Head and Neck Cancer. / Khuri, Fadlo R.; Jain, Sanjay R.

In: Seminars in Oncology, Vol. 31, No. 2 SUPPL. 4, 04.2004, p. 3-10.

Research output: Contribution to journalArticle

Khuri, FR & Jain, SR 2004, 'Novel Agents and Incremental Advances in the Treatment of Head and Neck Cancer', Seminars in Oncology, vol. 31, no. 2 SUPPL. 4, pp. 3-10.
Khuri, Fadlo R. ; Jain, Sanjay R. / Novel Agents and Incremental Advances in the Treatment of Head and Neck Cancer. In: Seminars in Oncology. 2004 ; Vol. 31, No. 2 SUPPL. 4. pp. 3-10.
@article{3f32be33872d45e98609053276f6722b,
title = "Novel Agents and Incremental Advances in the Treatment of Head and Neck Cancer",
abstract = "Cancer of the head and neck is an important medical problem, with approximately 46,500 cases predicted in the United States alone in 2003. Worldwide, more than 600,000 cases are anticipated. While several different histologic subtypes of head and neck cancer are seen in different parts of the world, more than 90{\%} of tumors diagnosed in the United States are squamous cell carcinomas. Major strides in the management of this disease have been made in the last decade. These include, but are not limited to, the evolution of organ preservation, the increasingly well recognized role of concurrent chemoradiation therapy as either definitive therapy for unresectable disease or adjuvant therapy for high-risk surgical disease, and significant improvements in cytotoxic chemotherapy. The role of chemotherapy in this disease has been a subject of debate. Chemotherapy is now routinely included in the multimodality treatment of unresectable disease of the oral pharynx, larynx, and oral cavity. There is now increasing evidence supporting the role of induction chemotherapy in head and neck cancer. As intensified chemotherapy and radiation therapy have improved local control, the increasing incidence of distant metastases has necessitated the need for enhanced systemic control. These approaches are the topics of extensive investigations.",
author = "Khuri, {Fadlo R.} and Jain, {Sanjay R.}",
year = "2004",
month = "4",
language = "English (US)",
volume = "31",
pages = "3--10",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 4",

}

TY - JOUR

T1 - Novel Agents and Incremental Advances in the Treatment of Head and Neck Cancer

AU - Khuri, Fadlo R.

AU - Jain, Sanjay R.

PY - 2004/4

Y1 - 2004/4

N2 - Cancer of the head and neck is an important medical problem, with approximately 46,500 cases predicted in the United States alone in 2003. Worldwide, more than 600,000 cases are anticipated. While several different histologic subtypes of head and neck cancer are seen in different parts of the world, more than 90% of tumors diagnosed in the United States are squamous cell carcinomas. Major strides in the management of this disease have been made in the last decade. These include, but are not limited to, the evolution of organ preservation, the increasingly well recognized role of concurrent chemoradiation therapy as either definitive therapy for unresectable disease or adjuvant therapy for high-risk surgical disease, and significant improvements in cytotoxic chemotherapy. The role of chemotherapy in this disease has been a subject of debate. Chemotherapy is now routinely included in the multimodality treatment of unresectable disease of the oral pharynx, larynx, and oral cavity. There is now increasing evidence supporting the role of induction chemotherapy in head and neck cancer. As intensified chemotherapy and radiation therapy have improved local control, the increasing incidence of distant metastases has necessitated the need for enhanced systemic control. These approaches are the topics of extensive investigations.

AB - Cancer of the head and neck is an important medical problem, with approximately 46,500 cases predicted in the United States alone in 2003. Worldwide, more than 600,000 cases are anticipated. While several different histologic subtypes of head and neck cancer are seen in different parts of the world, more than 90% of tumors diagnosed in the United States are squamous cell carcinomas. Major strides in the management of this disease have been made in the last decade. These include, but are not limited to, the evolution of organ preservation, the increasingly well recognized role of concurrent chemoradiation therapy as either definitive therapy for unresectable disease or adjuvant therapy for high-risk surgical disease, and significant improvements in cytotoxic chemotherapy. The role of chemotherapy in this disease has been a subject of debate. Chemotherapy is now routinely included in the multimodality treatment of unresectable disease of the oral pharynx, larynx, and oral cavity. There is now increasing evidence supporting the role of induction chemotherapy in head and neck cancer. As intensified chemotherapy and radiation therapy have improved local control, the increasing incidence of distant metastases has necessitated the need for enhanced systemic control. These approaches are the topics of extensive investigations.

UR - http://www.scopus.com/inward/record.url?scp=2342605530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342605530&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 3

EP - 10

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 4

ER -